Semaglutides Analysis Report 2024: Market Predicted to Surge to $36.87 Billion by 2028, Driven by Rising Diabetes Prevalence and Advancements in Treatment - Global Long-term Forecast to 2033 - ResearchAndMarkets.com

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

The semaglutides market is observing a significant growth trajectory, with recent reports underscoring an expansion from $20.54 billion in 2023 to an anticipated $23.07 billion in 2024, marking a compound annual growth rate (CAGR) of 12.3%. This robust growth is attributed to various factors, including an increase in diabetes cases worldwide, heightened investment in research and development, rising healthcare expenditures, and a more pronounced acceptance of injectable therapies. Moreover, the market is forecasted to further swell to $36.87 billion by 2028 with a steady CAGR of 12.4%.

Technological Innovations Set to Transform the Market

The emerging trends anticipated during this period include the integration of digital health technologies, advancements in artificial intelligence, and an increased demand for telemedicine and remote monitoring services. Developments in wearable technology, 3D printing, and blockchain for supply chain management are also expected to revolutionize the semaglutides market.

Strategic Acquisitions and Key Players

A noteworthy strategic acquisition in the industry occurred in May 2024, with Novo Holdings' purchase of Catalent for $16.5 billion. This move is intended to amalgamate Catalent's expertise in drug delivery with Novo Holdings' life sciences portfolio, fortifying its global healthcare market position. Leading pharmaceutical companies, including Pfizer Inc., Roche Holding AG, and Merck & Co. Inc, are continuously innovating to enhance diabetes treatment effectiveness and patient adherence, with a particular emphasis on advanced delivery systems and personalized medicine.

Geographic and Regional Market Insights

In 2023, North America dominated the semaglutides market share, but the Asia-Pacific region is projected to become the fastest-growing segment throughout the forecast period. The report covers detailed regional analysis, including key markets such as the United States, Canada, Japan, China, and the European Union.

About the Semaglutides Market

Semaglutide, primarily used to manage type 2 diabetes and obesity, is a GLP-1 receptor agonist that regulates blood sugar and appetite. With brands like Ozempic, Wegovy, and Rybelsus leading the market, the medication is delivered via injection and recently in oral form, providing options for improving patient quality of life and managing chronic conditions.

The information provided reflects the thorough analysis of the semaglutides market, its current status, and the anticipated future developments that stakeholders, potential investors, and participants in the healthcare industry may find of significant value.

Key Attributes:

Some of the major companies profiled in this Semaglutides market report include:

• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Biocon Limited
• Hanmi Pharmaceutical Co. Ltd.
• Intarcia Therapeutics Inc.
• Adocia SA

For more information about this report visit https://www.researchandmarkets.com/r/kbujwj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250107371002/en/